Science peels the onion of selenium effects on prostate carcinogenesis

Journal of the National Cancer Institute

Volumn 96, Issue 9, 2004, Pages 645-647

  Taylor, Philip R ^a   Parnes, Howard L ^a   Lippman, Scott M ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; GLUTATHIONE PEROXIDASE; PROSTATE SPECIFIC ANTIGEN; SELENIUM; SELENOPROTEIN; ANTINEOPLASTIC AGENT; DNA; PROTEIN;

CANCER INCIDENCE; CANCER RISK; CANCER STAGING; CLINICAL TRIAL; DIET SUPPLEMENTATION; DRUG MECHANISM; EDITORIAL; GENE IDENTIFICATION; GENETIC VARIABILITY; HUMAN; MALE; PHYLOGENY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN FUNCTION; RISK BENEFIT ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; ANIMAL; CONTROLLED CLINICAL TRIAL; DIET THERAPY; DNA DAMAGE; DRUG EFFECT; INCIDENCE; METABOLISM; NOTE; PROSTATE TUMOR; RANDOMIZED CONTROLLED TRIAL;

ANIMALS; ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC AGENTS; DIETARY SUPPLEMENTS; DNA DAMAGE; DNA, NEOPLASM; HUMANS; INCIDENCE; MALE; PROSTATIC NEOPLASMS; PROTEINS; RANDOMIZED CONTROLLED TRIALS; SELENIUM; SELENOPROTEINS; VITAMIN E;

EID: 2442513344     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/djh147     Document Type: Editorial

References (51)

1. Taylor PR, Albanes D. Selenium, vitamin E, and prostate cancer - ready for prime time? J Natl Cancer Inst 1998;90:1184-5.
2. Yoshizawa K, Willett WC, Morris SJ, Stampfer MJ, Spiegelman D, Rimm EB, et al. Study of prediagnostic selenium level in toenails and the risk of advanced prostate cancer. J Natl Cancer Inst 1998;90:1219-24.
3. Li H, Stampfer MJ, Giovannucci EL, Morris JS, Willett WC, Gaziano JM, et al. A prospective study of plasma selenium levels and prostate cancer risk. J Natl Cancer Inst 2004;96:696-703.
4. Nomura AM, Lee J, Stemmermann GN, Combs GF Jr. Serum selenium and subsequent risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2000;9:883-7.
5. Helzlsouer KJ, Huang HY, Alberg AJ, Hoffman S, Burke A, Norkus EP, et al. Association between alpha-tocopherol, gamma-tocopherol, selenium, and subsequent prostate cancer. J Natl Cancer Inst 2000;92:2018-23.
6. Brooks JD, Metter EJ, Chan DW, Sokoll LJ, Landis P, Nelson WG, et al. Plasma selenium level before diagnosis and the risk of prostate cancer development. J Urol 2001;166:2034-8.
7. Goodman GE, Schaffer S, Omenn GS, Chen C, King I. The association between lung and prostate cancer risk, and serum micronutrients: results and lessons learned from beta-carotene and retinol efficacy trial. Cancer Epidemiol Biomarkers Prev 2003;12:518-26.
8. van den Brandt PA, Zeegers MP, Bode P, Goldbohm RA. Toenail selenium levels and the subsequent risk of prostate cancer: a prospective cohort study. Cancer Epidemiol Biomarkers Prev 2003;12:866-71.
9. Rayman MP. The importance of selenium to human health. Lancet 2000; 356:233-41.
10. Clark LC, Combs GF Jr, Turnbull BW, Slate EH, Chalker DK, Chow J, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 1996;276:1957-63.
11. Duffield-Lillico AJ, Dalkin BL, Reid ME, Turnbull BW, Slate EH, Jacobs ET, et al. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU Int 2003;91:608-12.
12. Blot WJ, Li JY, Taylor PR, Guo W, Dawsey S, Wang GQ, et al. Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. J Natl Cancer Inst 1993;85:1483-92.
13. Schrauzer GN. Anticarcinogenic effects of selenium. Cell Mol Life Sci 2000;57:1864-73.
14. Behne D, Weiler H, Kyriakopoulos A. Effects of selenium deficiency on testicular morphology and function in rats. J Reprod Fertil 1996; 106:291-7.
15. Redman C, Xu MJ, Peng YM, Scott JA, Payne C, Clark LC, et al. Involvement of polyamines in selenomethionine induced apoptosis and mitotic alterations in human tumor cells. Carcinogenesis 1997;18:1195-202.
16. Redman C, Scott JA, Baines AT, Basye JL, Clark LC, Calley C, et al. Inhibitory effect of selenomethionine on the growth of three selected human tumor cell lines. Cancer Lett 1998;125:103-10.
17. Menter DG, Sabichi AL, Lippman SM. Selenium effects on prostate cell growth. Cancer Epidemiol Biomarkers Prev 2000;9:1171-82.
18. Klein EA, Lippman SM, Thompson IM, Goodman PJ, Albanes D, Taylor PR, et al. The selenium and vitamin E cancer prevention trial. World J Urol 2003;21:21-7.
19. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215-24.
20. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991;324:1156-61.
21. Lippman SM, Hong WK. Cancer prevention by delay. Clin Cancer Res 2002;8:305-13.
22. Lippman SM, Hong WK. Cancer prevention science and practice. Cancer Res 2002;62:5119-25.
23. Hatfield DL, Gladyshev VN. How selenium has altered our understanding of the genetic code. Mol Cell Biol 2002;22:3565-76.
24. Seo YR, Kelley MR, Smith ML. Selenomethionine regulation of p53 by a ref1-dependent redox mechanism. Proc Natl Acad Sci U S A 2002;99: 14548-53.
25. Meuillet E, Stratton S, Cherukuri DP, Goulet AC, Kagey J, Porterfield B, et al. Chemoprevention of prostate cancer with selenium: an update on current clinical trials and preclinical findings. J Cell Biochem 2004;91: 443-58.
26. Waters DJ, Shen S, Cooley DM, Bostwick DG, Qian J, Combs GF Jr, et al. Effects of dietary selenium supplementation on DNA damage and apoptosis in canine prostate. J Natl Cancer Inst 2003;95:237-41.
27. Sabichi AL, Lee JJ, Taylor RJ, Thompson IM Jr, Miles BJ, Basler JW, et al. Selenium accumulates in prostate tissue of prostate cancer patients after short-term administration of 1-selenomethionine. Proc Am Assoc Cancer Res 2002;43:1007-8.
28. Tapiero H, Townsend DM, Tew KD. The antioxidant role of selenium and seleno-compounds. Biomed Pharmacother 2003;57:134-44.
29. Ip C, Thompson HJ, Zhu Z, Ganther HE. In vitro and in vivo studies of methylseleninic acid: evidence that a monomethylated selenium metabolite is critical for cancer chemoprevention. Cancer Res 2000;60:2882-6.
30. Zhong W, Oberley TD. Redox-mediated effects of selenium on apoptosis and cell cycle in the LNCaP human prostate cancer cell line. Cancer Res 2001;61:7071-8.
31. Jiang C, Wang Z, Ganther H, Lu J. Caspases as key executors of methyl selenium-induced apoptosis (anoikis) of DU-145 prostate cancer cells. Cancer Res 2001;61:3062-70.
32. Venkateswaran V, Klotz LH, Fleshner NE. Selenium modulation of cell proliferation and cell cycle biomarkers in human prostate carcinoma cell lines. Cancer Res 2002;62:2540-5.
33. Dong Y, Zhang H, Hawthorn L, Ganther HE, Ip C. Delineation of the molecular basis for selenium-induced growth arrest in human prostate cancer cells by oligonucleotide array. Cancer Res 2003;63:52-9.
34. Dong Y, Lee SO, Zhang H, Marshall J, Gao AC, Ip C. Prostate specific antigen expression is down-regulated by selenium through disruption of androgen receptor signaling. Cancer Res 2004;64:19-22.
35. Driscoll DM, Copeland PR. Mechanism and regulation of selenoprotein synthesis. Annu Rev Nutr 2003;23:17-40.
36. Gallegos A, Berggren M, Gasdaska JR, Powis G. Mechanisms of the regulation of thioredoxin reductase activity in cancer cells by the chemopreventive agent selenium. Cancer Res 1997;57:4965-70.
37. Anestal K, Arner ES. Rapid induction of cell death by selenium-compromised thioredoxin reductase 1 but not by the fully active enzyme containing selenocytsteine. J Biol Chem 2003:278:15966-72.
38. Kryukov GV, Castellano S, Novoselov SV, Lobanov AV, Zehtab O, Guligo R, et al. Characterization of mammalian selenoproteomes. Science 2003; 300:1439-43.
39. Calvo A, Xiao N, Kang J, Best CJ, Leiva I, Emmert-Buck MR, et al. Alterations in gene expression profiles during prostate cancer progression: functional correlations to tumorigenicity and down-regulation of selenoprotein-P in mouse and human tumors. Cancer Res 2002;62:5325-35.
40. Kumaraswamy E, Malykh A, Korotkov KV, Kozyavkin S, Hu Y, Kwon SY, et al. Structure-expression relationships of the 15-kDa selenoprotein gene. Possible role of the protein in cancer etiology. J Biol Chem 2000; 275:35540-7.
41. Moscow JA, Schmidt L, Ingram DT, Gnarra J, Johnson B, Cowan KH. Loss of heterozygosity of the human cytosolic glutathione peroxidase I gene in lung cancer. Carcinogenesis 1994;15:2769-73.
42. Al Taie OH, Seufert J, Mork H, Treis H, Mentrup B, Thalheimer A, et al. A complex DNA-repeat structure within the Selenoprotein P promoter contains a functionally relevant polymorphism and is genetically unstable under conditions of mismatch repair deficiency. Eur J Hum Genet 2002; 10:499-504.
43. Villette S, Kyle JA, Brown KM, Pickard K, Milne JS, Nicol F, et al. A novel single nucleotide polymorphism in the 3′ untranslated region of human glutathione peroxidase 4 influences lipoxygenase metabolism. Blood Cells Mol Dis 2002;29:174-8.
44. Hu YJ, Korotkov KV, Mehta R, Hatfield DL, Rotimi CN, Luke A, et al. Distribution and functional consequences of nucleotide polymorphisms in the 3′-untranslated region of the human Sep15 gene. Cancer Res 2001;61: 2307-10.
45. Ratnasinghe D, Tangrea JA, Andersen MR, Barrett MJ, Virtamo J, Taylor PR, et al. Glutathione peroxidase codon 198 polymorphism variant increases lung cancer risk. Cancer Res 2000;60:6381-3.
46. Hu YJ, Diamond AM. Role of glutathione peroxidase 1 in breast cancer: loss of heterozygosity and allelic differences in the response to selenium. Cancer Res 2003;63:3347-51.
47. Kote-Jarai Z, Durocher F, Edwards SM, Hamoudi R, Jackson RA, Ardern-Jones A, et al. Association between the GCG polymorphism of the selenium dependent GPX1 gene and the risk of young onset prostate cancer. Prostate Cancer Prostatic Dis 2002;5:189-92.
48. Kumaraswamy E, Carlson BA, Morgan F, Miyoshi K, Robinson GW, Su D, et al. Selective removal of the selenocysteine tRNA [Ser]Sec gene (Trsp) in mouse mammary epithelium. Mol Cell Biol 2003;23:1477-88.
49. Hoque A, Albanes D, Lippman SM, Spitz MR, Taylor PR, Klein EA, et al. Molecular epidemiologic studies within the selenium and vitamin E cancer prevention trial (SELECT). Cancer Causes Control 2001;12:627-33.
50. Benton D. Selenium intake, mood and other aspects of psychological functioning. Nutr Neurosci 2002;5:363-74.
51. Duffield-Lillico AJ, Slate EH, Reid ME, Turnbull BW, Wilkins PA, Combs GF Jr, et al. Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomized trial. J Natl Cancer Inst 2003;95:1477-81.